In September 2023, the FDA granted an EUA for an updated Pfizer-BioNTech mRNA COVID-19 vaccine for use in children aged 6 months through 4 years of age to target the Omicron variant XBB.1.5.
The FDA originally issued an EUA for a 3mcg dose of Pfizer-BioNTech mRNA COVID-19 vaccine containing the original SARS-CoV-2 strain for infants and young children aged 6 months through 4 years of age in June 2022, and a bivalent booster dose containing the original SARS-CoV-2 and Omicron strains BA.4/BA.5 in December 2022. These previously authorized vaccine formulations are no longer available for use in the U.S.
According to the Fact Sheet provided by the FDA, each 0.3 mL dose of the vaccine contains 3mcg of nucleoside modified messenger RNA (mRNA) that encodes the pre-fusion stabilized Spike glycoprotein (S) of SARS-CoV-2 virus.
Each dose also contains the following ingredients: 9.4 mg sucrose, 0.02 mg tromethamine, 0.12 mg tromethamine hydrochloride; lipids (0.04 mg ((4- hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), 0.005 mg 2[(polyethylene glycol)-2000- N,N-ditetradecylacetamide, 0.01 mg 1,2-distearoyl-sn-glycero-3-phosphocholine, and 0.02 mg cholesterol). The sterile 0.9 percent sodium chloride diluent adds 1.88 mg of sodium chloride per dose. The vaccine vial stoppers are free of latex and the vaccine does not contain a preservative.
Children aged six months through four years are recommended to receive at least 3-doses of Pfizer-BioNTech mRNA COVID-19 vaccine. The number of recommended doses of the authorized 3mcg Pfizer-BioNTech COVID-19 vaccine targeting Omicron variant XBB.1.5 will depend on previously authorized doses of COVID-19 vaccine.
Pfizer-BioNTech COVID-19 vaccine has not been studied for its potential to cause cancer, genotoxicity or male infertility.
The CDC’s ACIP voted to approve use of the 3mcg dose of the Pfizer-BioNTech 2023-2024 mRNA COVID-19 vaccine targeting the Omicron variant XBB.1.5 for use in all children aged 6 months through 4 years of age on September 12, 2023.